|
|
| General |
| Study Status |
Completed |
Application Number /
Requirement Number |
P170043 / PAS001 |
| Date Original Protocol Accepted |
04/16/2019
|
| Date Current Protocol Accepted |
04/30/2020
|
| Study Name |
Extended f/u Premarket Cohort
|
| Device Name |
iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
New Data Collection
|
| Comparison Group |
Objective Performance Criterion
|
| Analysis Type |
Analytical
|
| Study Population |
Adult: >21
|
| Detailed Study Protocol Parameters |
| Study Objectives |
The objective of this post approval study (PAS) is to evaluate the long -term rate of clinically relevant complications associated with iStent inject® placement and stability in subjects who have completed participation of the IDE clinical trial (GC-008). This is a long-term safety, multicenter, observational study with no planned interventions.
|
| Study Population |
Randomized subjects in the GC-008 study who are able to understand the study requirements, willing to follow study instructions and are willing to return for required study follow-up visits.
|
| Sample Size |
Up to 475 eyes of 475 subjects. This is based on the number of randomized subjects who consented to 36-month follow-up in study Protocol the GC-008 and study followed for 24 months. Subjects will need to meet the study inclusion criteria.
|
| Key Study Endpoints |
Safety Endpoint:
The rate of clinically relevant complications associated with iStent inject placement and stability as determined at 60 months. Specific
device-related complications include clinical sequelae resulting from device position including, but not limited to:
Secondary surgical intervention (SSI) to modify device position
(e.g., repositioning or explantation)
Corneal endothelial touch by device
Corneal edema leading to best-spectacle corrected visual acuity
loss (BSCVA loss) > 2 lines at the Month 60 visit, in comparison
with preoperative BSCVA
Other Safety Outcomes:
Rate of occurrence of sight-threatening adverse events including:
Persistent (at time of study exit) BSCVA loss = 3 lines
compared to best recorded BSCVA at any postoperative visit
Endophthalmitis
Corneal decompensation
Retinal detachment
Severe choroidal hemorrhage or detachment or aqueous misdirection
Rate of ocular secondary surgical interventions (SSI)
Rate of other adverse events including:
Increase from baseline IOP of greater than or equal to 10 mmHg at any time greater than or equal to 30 days postoperative
BSCVA loss greater than or equal to 2 lines at Month 60 compared to screening
BSCVA loss greater than or equal to 2 lines at Month 60 compared to best recorded
BSCVA at any postoperative visit
Device movement, defined as a stent not visible in the original location, that does not result in clinically relevant complications as described above (e.g., SSI to modify device position, corneal endothelial touch by device, or corneal edema leading to BSCVA loss > 2 lines at the Month 60 visit
compared to preoperative BSCVA), and that is not attributable to any one or more of the following:
- variations in gonioscopy, optical coherence tomography
(OCT) or ultrasonic biomicroscopy (UBM) (or other standard imaging methods) viewing angle or illumination
- changes in angle anatomy due to concomitant findings such as resolution of hyphema
- changes in anterior chamber depth
- development of focal peripheral anterior synechiae (PAS)
|
| Follow-up Visits and Length of Follow-up |
60 months post-randomization in the IDE trial
|
| Interim or Final Data Summary |
| Interim Results |
Not reported
|
| Actual Number of Patients Enrolled |
8
|
| Actual Number of Sites Enrolled |
25
|
| Patient Follow-up Rate |
2% (8/475)
|
| Study Strengths & Weaknesses |
This information will be included in the final report
|
